IMUNON reports positive results for IMNN-001 in advanced ovarian cancer and IMNN-101 for COVID-19.

From GlobeNewswire: 2025-02-27 08:05:00

IMNN-001 is the first immunotherapy to show significant overall survival benefits in advanced ovarian cancer, with patients achieving an average survival of 13 months. A Phase 3 pivotal trial is set to begin in Q1 2025. IMUNON, Inc. reported financial results for 2024, highlighting progress in advancing IMNN-001 development. Recent data from the OVATION 2 Study showed a 20% increase in IL-12 levels in patients treated with IMNN-001, along with positive CMC meeting outcomes with the FDA. IMUNON also added Dr. Douglas V. Faller as Chief Medical Officer to support future clinical programs. Financially, the company reported a net loss of $18.6 million for 2024, with sufficient capital resources to fund operations into late Q2 2025.

In other news, IMUNON announced positive results from a Phase 1 clinical trial of IMNN-101, a DNA plasmid vaccine targeting the SARS-CoV-2 Omicron XBB1.5 spike antigen. The vaccine demonstrated safety and induced a strong immune response in participants, highlighting the potential of the PlaCCine technology platform. The Company plans to explore partnerships for further development of the vaccine. For more information, visit www.imunon.com.

The Company will host a conference call today at 11:00 a.m. ET to discuss 2024 financial results and business updates. Participants can join the call by dialing the provided numbers or accessing the live webcast. The call will be archived for replay until March 12, 2025. IMUNON is a clinical-stage biotechnology company focused on innovative treatments for various diseases, including IMNN-001 for advanced ovarian cancer and IMNN-101 for COVID-19. Forward-looking statements in this release are made in accordance with safe harbor provisions. Contact IMUNON for more details.



Read more at GlobeNewswire: IMUNON Reports 2024 Financial Results and Provides Business